Treatment of Type II
diabetes mellitus, mixed dyslipidemia, atherosclerosis,
and metabolic syndrome.
in vivo
Peliglitazar, is a novel dual α/γperoxisome proliferator-activated receptor (PPAR) activator. It has been shown that Peliglitazar has both glucose and lipid-lowering effects when tested in animal models of diabetes and dyslipidemia[1].
